GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Market Cap	133.26B
Revenue (ttm)	61.19B
Net Income (ttm)	6.54B
Shares Out	318.47M
EPS (ttm)	20.52
PE Ratio	20.39
Forward PE	n/a
Dividend	10.00 (2.39%)
Ex-Dividend Date	Apr 18, 2025

Volume	146,294
Average Volume	253,798
Open	418.00
Previous Close	417.68
Day's Range	417.68 - 424.00
52-Week Range	81.10 - 444.00
Beta	0.27
RSI	65.42
Earnings Date	Apr 28, 2025

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan and internationally. It deals in anti-infective, dermatology, respiratory, analgesics, immunology, oncology, urology, HIV, vaccines, and analgesics therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Cutivate, Calpol, Boostrix, Rotarix, Havrix, and Synflorix. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc.

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 2001
• Employees: 1,700
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: GLAXO

Financial Performance

In 2024, GlaxoSmithKline Pakistan's revenue was 61.19 billion, an increase of 23.21% compared to the previous year's 49.66 billion. Earnings were 6.54 billion, an increase of 1124.09%.